Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 12840 Prague, Czech Republic.
Centre of Occupational Health, National Institute of Public Health, Šrobárova 48, 100 42 Prague 10, Czech Republic.
Chem Res Toxicol. 2020 Nov 16;33(11):2804-2818. doi: 10.1021/acs.chemrestox.0c00198. Epub 2020 Oct 20.
The plant extract aristolochic acid (AA), containing aristolochic acid I (AAI) and II (AAII) as major components, causes aristolochic acid nephropathy and Balkan endemic nephropathy, unique renal diseases associated with upper urothelial cancer. Differences in the metabolic activation and detoxification of AAI and AAII and their effects on the metabolism of AAI/AAII mixture in the plant extract might be of great importance for an individual's susceptibility in the development of AA-mediated nephropathies and malignancies. Here, we investigated metabolism of AAI and AAII after ip administration to Wistar rats as individual compounds and as AAI/AAII mixture using high performance liquid chromatography/electrospray ionization mass spectrometry. Experimental findings were supported by theoretical calculations using density functional theory. We found that exposure to AAI/AAII mixture affected the generation of their oxidative and reductive metabolites formed during Phase I biotransformation and excreted in rat urine. Several Phase II metabolites of AAI and AAII found in the urine of exposed rats were also analyzed. Our results indicate that AAI is more efficiently metabolized in rats than AAII. Whereas AAI is predominantly oxidized during metabolism, its reduction is the minor metabolic pathway. In contrast, AAII is mainly metabolized by reduction. The oxidative reaction only occurs if aristolactam II, the major reductive metabolite of AAII, is enzymatically hydroxylated, forming aristolactam Ia. In AAI/AAII mixture, the metabolism of AAI and AAII is influenced by the presence of both AAs. For instance, the reductive metabolism of AAI is increased in the presence of AAII while the presence of AAI decreased the reductive metabolism of AAII. These results suggest that increased bioactivation of AAI in the presence of AAII also leads to increased AAI genotoxicity, which may critically impact AAI-mediated carcinogenesis. Future studies are needed to explain the underlying mechanism(s) for this phenomenon.
植物提取物马兜铃酸(AA),主要包含马兜铃酸 I(AAI)和 II(AAII),可引起马兜铃酸肾病和巴尔干地方性肾病,这两种独特的肾脏疾病均与上尿路上皮癌相关联。AAI 和 AAII 的代谢激活和解毒的差异及其对植物提取物中 AAI/AAII 混合物代谢的影响,可能对个体在 AA 介导的肾病和恶性肿瘤发展中的易感性具有重要意义。在这里,我们使用高效液相色谱/电喷雾电离质谱法,研究了 Wistar 大鼠单次腹腔注射 AAI 和 AAII 作为单一化合物和 AAI/AAII 混合物后的代谢情况。实验结果得到了密度泛函理论理论计算的支持。我们发现,暴露于 AAI/AAII 混合物会影响其在 I 期生物转化过程中形成的氧化和还原代谢物的生成,并在大鼠尿液中排泄。还分析了暴露于 AA 的大鼠尿液中发现的几种 AAI 和 AAII 的 II 期代谢物。我们的研究结果表明,AAI 在大鼠体内比 AAII 更有效地代谢。AAI 的代谢主要是氧化,而其还原是次要的代谢途径。相比之下,AAII 主要通过还原代谢。只有当 AAII 的主要还原代谢物 aristolactam II 被酶促羟化,形成 aristolactam Ia 时,才会发生氧化反应。在 AAI/AAII 混合物中,AAI 和 AAII 的代谢受两者的存在影响。例如,AAII 的存在会增加 AAI 的还原代谢,而 AAI 的存在会降低 AAII 的还原代谢。这些结果表明,AAII 存在时 AAI 的生物活化增加也会导致 AAI 的遗传毒性增加,这可能会对 AA 介导的致癌作用产生重大影响。需要进一步的研究来解释这种现象的潜在机制。